nicorandil

Nicorandil (SG-75) 是一种有效的钾通道激活剂，靶向血管核苷二磷酸依赖性 K+通道和心脏 ATP 敏感 K+通道 (KATP)。Nicorandil 是一种烟酰胺酯，具有血管舒张和心脏保护作用，并具有治疗心绞痛和缺血性心脏病的潜力。

Nicorandil-d4 is intended for use as an internal standard for the quantification of nicorandil by GC- or LC-MS. Nicorandil is an activator of sulfonylurea receptor 2B (SUR2B) linked to ATP-sensitive potassium channel Kir6.2 (EC50 = ~10 µM) and a nitric oxide (NO) donor. It is selective for SUR2B/Kir6.2 over the SUR2A/Kir6.2 channel (EC50 = >500 µM). Nicorandil activates soluble guanylate cyclase in a cell-free assay and relaxes partially depolarized isolated bovine coronary artery strips (EC50 = 4.4 µM). It decreases mean blood pressure, coronary resistance, and heart rate, as well as increases coronary sinus outflow, in dogs when administered intravenously at a dose of 1 mg/kg. Nicorandil increases survival and decreases infarct size in a rabbit model of myocardial ischemia-reperfusion injury induced by left coronary artery occlusion. Formulations containing nicorandil have been used in the treatment of angina pectoris.

Nicorandil N-oxide, a metabolite of nicorandil, functions as an activator of the ATP-sensitive potassium channel Kir6.2 (SUR2B/Kir6.2) and is associated with the sulfonylurea receptor 2B (SUR2B), while also serving as a nitric oxide donor.

SG 209是nicorandil的类似物，可作为K+通道开放剂和无硝酸盐的冠状血管扩张剂。

Quizartinib, also know as AC220 and AC010220, is an orally available FLT3 / STK1 inhibitor with potential antineoplastic activity. Class III receptor tyrosine kinase inhibitor AC220 selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis. Mutations in FLT3, resulting in constitutive activation, are the most frequent genetic alterations in acute myeloid leukemia (AML) and occur in approximately one-third of AML cases.